Studies Find Limited Support For Genotyping-Guided Warfarin Dosing
This article was originally published in The Gray Sheet
Executive Summary
The overall message of three trials published recently in The New England Journal of Medicine: “This pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or, at best, marginal usefulness, given the cost and effort required to perform this testing,” according to an editorial also in NEJM.
You may also be interested in...
Biomarkers In Labeling Lack Clinical Utility Evidence
FDA-approved labels for more than 100 drugs feature pharmacogenomic biomarker data, but only one-sixth of those biomarkers are supported by data showing a clear association with health benefits, a JAMA study found. Researchers recommend stricter standards and a standardized pharmacogenomics section of labeling.
CMS Director To Diagnostics Industry: Prove Your Cancer Tests Work
“Why are insurers so reluctant to get enthusiastic and really embrace molecular diagnostics?” asked the director of CMS’ coverage and analysis group at a recent cancer diagnostics symposium. “Because half the time we have no idea what on earth we’re paying for.”
Raising The Bar For Anticoagulants? Warfarin Genotype Results Announced
Results of a prospective observational study conducted by the pharmacy benefit manager Medco and the Mayo Clinic link more precise warfarin dosing through genotyping to a 30% reduction in hospitalization rates from any cause within six months of starting the drug